Quantitative insights into tirzepatide and semaglutide using longitudinal systems modeling
Authors' conclusion
Greater suppression of hepatic glucose production was associated with greater efficacy of tirzepatide 15 mg versus semaglutide 1 mg in improving fasting glucose.
Study context
- Population
- Patients with T2D in a 28-week clinical trial
- Comparison
- Tirzepatide 15 mg vs semaglutide 1 mg
- Outcome
- Longitudinal metabolic mechanisms of fasting glucose control
Methodological detailslongitudinal systems modeling, model-based analysis of 28-week clinical trial data
- Longitudinal systems modeling
- Model-based analysis of 28-week clinical trial data
Main finding
As reported in the abstract
- Beta-cell function (HOMA-B) initially increased and then declined as insulin sensitivity improved
- Tirzepatide's superior fasting glucose control vs semaglutide was driven primarily by greater insulin-independent suppression of hepatic glucose production (HGP)
- Low responders exhibited deficient HGP suppression
Further findings
Simulations
- Enhancing HGP suppression improved fasting glucose without inducing β-cell stress associated with sustained hypersecretion
- Enhanced weight loss accelerated early glycemic improvement but did not further reduce long-term fasting glucose
Original publication
Quantitative insights into tirzepatide and semaglutide using longitudinal systems modeling. J Clin Endocrinol Metab. Published 21 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →